A. When there is a compelling need to minimize weight gain or promote weight loss B. When there is a compelling need to minimize hypoglycemia C. When there is a compelling need to decrease cardiovascular risk in patients with established atherosclerotic cardiovascular disease (ASCVD) D. When drug cost is a major consideration E. Unsure

A. Long-acting GLP-1 RAs are all available in single-use, once-weekly disposable pen devices, while short-acting GLP-1 RAs are all available in multi-use, once-daily disposable pen devices B. Long-acting GLP-1 RAs target both fasting and post-meal glucose levels, while short-acting GLP-1 RAs primarily target post-meal glucose levels C. Short-acting GLP-1 RAs have lower rates of gastrointestinal side effects than long-acting GLP-1 RAs D. Short-acting GLP-1 RAs are more effective at lowering A1C than long-acting GLP-1 RAs E. Unsure

A. Oral semaglutide should be taken with food to increase absorption B. Oral semaglutide should be taken with at least 8 ounces of water to ensure absorption C. Taking oral semaglutide at the same time as levothyroxine can increase thyroxine levels D. Taking oral semaglutide at the same time as atorvastatin can increase semaglutide levels E. Unsure

A. Dulaglutide and semaglutide subcutaneous (SC) injection B. Dulaglutide and oral semaglutide C. Exenatide XR and oral semaglutide D. Oral semaglutide and semaglutide SC injection E. Unsure

A. CV benefits are achieved as glycemic targets are reached B. CV benefits are achieved after 4–5 half-lives of the medication have passed C. CV benefits are achieved after 3–6 months of GLP-1 RA use D. CV benefits are achieved after 12–18 months of GLP-1 RA use E. Unsure